Human monoclonal antibodies against cd20
CA 3029035 C · Owner: Genmab A/S · Inventors: Parren, Paul; Ruuls, Sigrid; Huang, Haichun
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Herein is provided an isolated human monoclonal antibody which binds to human CD20, and which comprises: the VH CDR1 sequence as set forth in SEQ ID N025 the VH , CDR2 , sequence as set forth in SEQ ID NO:26 the VH CDR3 sequence as set forth in , SEQ ID N027 the VL CDR1 sequence as set forth in SEQ ID N028 the VL CDR2 sequence as set , forth in SEQ ID N029, and the VL CDR3 sequence as set forth in SEQ ID NO:30. Also described are , antibodies that compete for binding to an epitope on human CD20 defmed by the aforementioned , antibody. Also provided are cells producing said antibodies compositions , comprising said , antibodies bispecific molecules comprising said antibodies and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 17, 2003 and granted March 7, 2023. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.